First Real-World Experience With Bigfoot Unity: A 6-Month Retrospective Analysis

Area of Science:

• Endocrinology
• Diabetes Technology
• Clinical Informatics

Background:

• The Bigfoot Unity Diabetes Management System is an FDA-cleared smart pen cap.
• It integrates continuous glucose monitoring (CGM) data and provides real-time alerts.
• Clinician-directed insulin dose recommendations are a key feature.

Purpose of the Study:

• To analyze real-world clinical outcomes of the Bigfoot Unity system.
• To evaluate glycemic control in patients using the smart pen cap for insulin therapy.
• To assess hypoglycemia events and user interaction with the system.

Main Methods:

• Analysis of real-world clinical data from an initial cohort of 58 patients.
• Study duration of 6 months for patients on multiple daily injection insulin therapy.
• Examination of glycemic control metrics, including time spent in hypoglycemia.

Main Results:

• The study cohort comprised primarily adults (average age 62) with type 2 diabetes.
• Patients demonstrated close adherence to established glycemic targets.
• A relatively short duration of time spent in the hypoglycemic range was observed.

Conclusions:

• The Bigfoot Unity smart pen cap system shows promise in improving diabetes management.
• Real-world data suggests effective glycemic control and reduced hypoglycemia.
• The system facilitates adherence to therapeutic goals in type 2 diabetes patients.